[go: up one dir, main page]

FI104069B1 - Process for the preparation of therapeutically useful 3- (phenyl- or cycloalkyl) -3-hydroxy-1-phenylsulfonyl-2-indoline carboxamide derivatives - Google Patents

Process for the preparation of therapeutically useful 3- (phenyl- or cycloalkyl) -3-hydroxy-1-phenylsulfonyl-2-indoline carboxamide derivatives

Info

Publication number
FI104069B1
FI104069B1 FI931476A FI931476A FI104069B1 FI 104069 B1 FI104069 B1 FI 104069B1 FI 931476 A FI931476 A FI 931476A FI 931476 A FI931476 A FI 931476A FI 104069 B1 FI104069 B1 FI 104069B1
Authority
FI
Finland
Prior art keywords
alkyl
mono
substd
halogen
opt
Prior art date
Application number
FI931476A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI104069B (en
FI931476A0 (en
FI931476A7 (en
Inventor
Jean Wagnon
Claude Plouzane
Claudine Serradeil-Legal
Dino Nisato
Bernard Tonnerre
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of FI931476A0 publication Critical patent/FI931476A0/en
Publication of FI931476A7 publication Critical patent/FI931476A7/en
Priority to FI980175A priority Critical patent/FI107048B/en
Application granted granted Critical
Publication of FI104069B publication Critical patent/FI104069B/en
Publication of FI104069B1 publication Critical patent/FI104069B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

3-Hydroxy-1-indolinyl sulphones of formula (I) and their salts are new: In (I), R1 = halogen, 1-4C alkyl, OH, 1-4C alkoxy, benzyloxy, CN, CF3, NO2 or NH2; R2 = 1-6C alkyl; 3-7C cycloalkyl,; 5-7C cycloalkenyl; phenyl opt. substd. by 1-4C alkyl, 1-4C alkoxy, halogen, CF3 and/or NH2; or nitrophenyl opt. substd. by CF3, 1-4C alkyl or halogen; R5 = 1-4C alkyl; 1- or 2-naphthyl;5-dimethylamino-1-naphthyl; phenyl opt. substd. by halogen, CF3, NH2, mono- or di (1-4C alkyl) amino, OH, 1-4C alkoxy, 2-4C alkenyloxy, 1-4C alkylthio, CF3, benzyloxy, CN, COOH, 2-5C alkoxycarbonyl, CONH2, mono- or di (1-4C alkyl)carbamoyl or 1-4C alkanoylamino; or nitrophenyl opt. substd. by CF3, 2-4C alkenyloxy, halogen, 1-4C alkyl, 1-4C alkoxy, 1-4C alkylthio, OCF3 or benzyloxy; R6 = 1-6C alkyl or R7; R7 = 1-R-4-piperidinyl, 1-R-3-azetidinyl or (CH2)rR'; R = H, 1-4C alkyl, benzyloxycarbonyl or 2-5C alkoxycarbonyl; R1 = pyridyl, OH, NH2, mono- or di(1-4C alkyl)amino, COOH, 2-5C alkoxycarbonyl, benzylcarbonyl, CONH2 or mono- or di(1-4C alkyl)carbamoyl; or NR6R7 = morpholino; thiomorpholino; thiazolidinyl or 2,2-dimethylthiazolidinyl opt. substd. by R8; 1-piperazinyl opt. 4-substd. by R"8; and unsatd. 5-membered monoaza ring substd. by R8; or a satd. 3- to 7-membered monoaza ring substd. by R8 and R9; R8 = R'8 or (CH2)rA1, where A1 = OH, NH2 or mono- or di(1-4C alkyl)amino; R'8 = (CH2)qA2, where A2 = COOH, 2-5C alkoxycarbonyl, benzyloxycarbonyl, CONH2, CONHOH, mono- or di(1-4C alkyl)carbamoyl, CSNH2 or mono- or di(1-4C alkyl)thiocarbamoyl; R"8 = R8' or (CH2)A3, where A3 = NH2 or mono- or di(1-4C alkyl)amino; R9 = H, halogen, (CH2rOR10), (CH2)rNR11R12, (CH2)SCONR11R'11 or N3; R10 = H, 1-4C alkyl, mesyl or tosyl; R11, R'11 and R12 = H or 1-4C alkyl, or R11 = H, and R12 = benzyloxycarbonyl or 2-5C alkoxycarbonyl; n and m = 0-2; q = 0-3; r = 0-3, but not 0 when R8 or R9 is in a position alpha to the intracyclic amidic nitrogen (SiC); s = 0 or 1.
FI931476A 1991-08-02 1993-04-01 Process for the preparation of therapeutically useful 3- (phenyl- or cycloalkyl) -3-hydroxy-1-phenylsulfonyl-2-indoline carboxamide derivatives FI104069B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI980175A FI107048B (en) 1991-08-02 1998-01-27 2-sulfonamidofenonderivat

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9109908A FR2679903B1 (en) 1991-08-02 1991-08-02 DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
FR9109908 1991-08-02
PCT/FR1992/000758 WO1993003013A1 (en) 1991-08-02 1992-07-31 Indoline derivatives having an amide function, their preparation, and pharmaceutical compositions containing them
FR9200758 1992-07-31

Publications (4)

Publication Number Publication Date
FI931476A0 FI931476A0 (en) 1993-04-01
FI931476A7 FI931476A7 (en) 1993-04-01
FI104069B FI104069B (en) 1999-11-15
FI104069B1 true FI104069B1 (en) 1999-11-15

Family

ID=9415909

Family Applications (2)

Application Number Title Priority Date Filing Date
FI931476A FI104069B1 (en) 1991-08-02 1993-04-01 Process for the preparation of therapeutically useful 3- (phenyl- or cycloalkyl) -3-hydroxy-1-phenylsulfonyl-2-indoline carboxamide derivatives
FI980175A FI107048B (en) 1991-08-02 1998-01-27 2-sulfonamidofenonderivat

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI980175A FI107048B (en) 1991-08-02 1998-01-27 2-sulfonamidofenonderivat

Country Status (28)

Country Link
EP (1) EP0526348B1 (en)
JP (1) JP2633085B2 (en)
KR (1) KR100241583B1 (en)
AT (1) ATE163289T1 (en)
AU (2) AU658664B2 (en)
BR (1) BR9205336A (en)
CA (2) CA2093221C (en)
CZ (1) CZ288173B6 (en)
DE (1) DE69224450T2 (en)
DK (1) DK0526348T3 (en)
ES (1) ES2117038T3 (en)
FI (2) FI104069B1 (en)
FR (1) FR2679903B1 (en)
HU (2) HUT68927A (en)
IL (3) IL117592A (en)
LT (1) LT3064B (en)
LV (1) LV10091B (en)
MX (1) MX9204487A (en)
MY (1) MY110517A (en)
NO (1) NO180047C (en)
NZ (1) NZ243795A (en)
PH (1) PH30661A (en)
RU (1) RU2104268C1 (en)
SG (1) SG47501A1 (en)
SK (1) SK283463B6 (en)
UA (1) UA27238C2 (en)
WO (1) WO1993003013A1 (en)
ZA (1) ZA925781B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665441B1 (en) * 1990-07-31 1992-12-04 Sanofi Sa N-SULFONYL INDOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
FR2708608B1 (en) * 1993-07-30 1995-10-27 Sanofi Sa N-sulfonylbenzimidazolone derivatives, their preparation, pharmaceutical compositions containing them.
FR2756736B1 (en) * 1996-12-05 1999-03-05 Sanofi Sa PHARMACEUTICAL COMPOSITIONS CONTAINING N-SULFONYL INDOLINE DERIVATIVES
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
CN1265670A (en) * 1997-07-31 2000-09-06 伊兰药品公司 Dipeptides and related compounds that inhibit VLA-4 mediated leukocyte adhesion
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
CN1265669A (en) * 1997-07-31 2000-09-06 伊兰药品公司 Compounds Inhibiting Leukocyte Adhesion Mediated by VLA-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
JP2001512139A (en) * 1997-07-31 2001-08-21 エラン・ファーマシューティカルズ・インコーポレーテッド Sulfonylated dipeptide compounds that inhibit leukocyte adhesion mediated by VLA-4
FR2775598A1 (en) 1998-03-06 1999-09-10 Sanofi Sa PHARMACEUTICAL COMPOSITIONS COMPRISING A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V1A RECEPTORS AND A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V2 RECEPTORS
FR2778103A1 (en) * 1998-04-29 1999-11-05 Sanofi Sa PHARMACEUTICAL COMPOSITIONS CONTAINING IN ASSOCIATION A V1A ARGININE-VASOPRESSIN ANTAGONIST AND AN ANGIOTENSIN II AT1 RECEPTOR ANTAGONIST
FR2786486B3 (en) * 1998-11-16 2000-12-08 Sanofi Sa PROCESS FOR THE PREPARATION OF (2S) -1 - [(2R, 3S) -5-CHLORO-3- (2- CHLOROPHENYL) -1- (3,4-DIMETHOXY BENZENESULFONYL) -3-HYDROXY- 2,3-DIHYDRO- 1H-INDOLE-2-CARBONYL] PYRROLIDINE-2-CARBOXAMIDE, ITS SOLVATES AND / OR HYDRATES
BR0007663A (en) 1999-01-22 2002-05-07 Elan Pharm Inc Acyl derivatives for use in the treatment of diseases related to vla-4
AR035476A1 (en) 1999-01-22 2004-06-02 Elan Pharm Inc HETEROARILO AND HETEROCICLIC COMPOUNDS WITH FUSIONED RING, WHICH INHIBIT THE ADHESION OF LEUKOCYTES THROUGH VLA-4, PHARMACEUTICAL COMPOSITIONS, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A BIOLOGICAL METHOD 4
CA2359114A1 (en) * 1999-01-25 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
GB9902461D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
FR2792834A1 (en) * 1999-04-29 2000-11-03 Sanofi Sa USE OF SR 49059, ITS PHARMACEUTICALLY ACCEPTABLE SOLVATES AND / OR HYDATES FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OR PREVENTION OF RAYNAUD PHENOMENON
FR2805536B1 (en) * 2000-02-25 2002-08-23 Sanofi Synthelabo NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2805992A1 (en) * 2000-03-08 2001-09-14 Sanofi Synthelabo Oral administration of N-sulfonyl-indoline derivative to treat central nervous system, cardiovascular or gastric disorders, using polyethylene glycol, polysorbate and poloxamer as solubilizers for high bioavailability
ATE464292T1 (en) 2000-10-17 2010-04-15 Merck Serono Sa PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES
WO2002044179A1 (en) 2000-11-28 2002-06-06 Yamanouchi Pharmaceutical Co., Ltd. 1,4,5,6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof
JP4044740B2 (en) * 2001-05-31 2008-02-06 信越化学工業株式会社 Resist material and pattern forming method
CA2469042A1 (en) 2001-12-20 2003-07-03 Applied Research Systems Ars Holding N.V. Triazoles as oxytocin antagonists
CA2784937A1 (en) 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
WO2004026830A1 (en) * 2002-09-17 2004-04-01 F. Hoffmann-La Roche Ag 2,7-substituted indoles and their use as 5-ht6 modulators
EP1542973B1 (en) * 2002-09-17 2008-07-30 F. Hoffmann-La Roche Ag 2,4-substituted indoles and their use as 5-ht6 modulators
RU2334735C2 (en) * 2002-10-11 2008-09-27 Актелион Фармасьютиклз Лтд. Sulphonyl aminoacetic acid derivatives and their application as orexin receptor antagonists
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
CA2500492C (en) 2002-11-18 2010-03-16 Solomon Ungashe Aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
CA2583660C (en) * 2004-10-27 2013-02-12 Toshiaki Yamaguchi Indoline compound and process for producing the same
ZA200803016B (en) 2005-09-29 2009-10-28 Elan Pharmaceuticals Inc Wyeth Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
ATE493405T1 (en) 2005-09-29 2011-01-15 Elan Pharm Inc PYRIMIDINYLAMIDE COMPOUNDS THAT INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4
WO2007101165A1 (en) 2006-02-27 2007-09-07 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
JP2012525336A (en) 2009-04-27 2012-10-22 エラン ファーマシューティカルズ,インコーポレイテッド Alpha-4 integrin pyridinone antagonist
HU231206B1 (en) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepines
TW201938171A (en) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 Tricyclic compounds as vasopressin V1a receptor antagonists
TW202542165A (en) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 Macrocyclic orexin agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
US4479963A (en) * 1981-02-17 1984-10-30 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
DE3705934A1 (en) * 1987-02-25 1988-09-08 Nattermann A & Cie Indolyl derivatives, processes for their preparation, and their use as medicaments
FR2665441B1 (en) * 1990-07-31 1992-12-04 Sanofi Sa N-SULFONYL INDOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.

Also Published As

Publication number Publication date
ZA925781B (en) 1993-03-02
WO1993003013A1 (en) 1993-02-18
NO931262L (en) 1993-05-26
IL102703A (en) 1997-03-18
CZ68293A3 (en) 1994-01-19
UA27238C2 (en) 2000-08-15
FI104069B (en) 1999-11-15
MY110517A (en) 1998-07-31
EP0526348B1 (en) 1998-02-18
LV10091B (en) 1995-04-20
DE69224450D1 (en) 1998-03-26
FI931476A0 (en) 1993-04-01
FI980175A0 (en) 1998-01-27
AU691223B2 (en) 1998-05-14
ES2117038T3 (en) 1998-08-01
LTIP114A (en) 1994-06-15
LV10091A (en) 1994-05-10
NO180047C (en) 1997-02-05
FI107048B (en) 2001-05-31
CA2206776C (en) 2002-02-26
KR100241583B1 (en) 2000-03-02
CA2206776A1 (en) 1993-02-03
FR2679903B1 (en) 1993-12-03
PH30661A (en) 1997-09-16
ATE163289T1 (en) 1998-03-15
DK0526348T3 (en) 1998-11-23
NO931262D0 (en) 1993-04-01
SK283463B6 (en) 2003-08-05
NO180047B (en) 1996-10-28
AU2475892A (en) 1993-03-02
FR2679903A1 (en) 1993-02-05
SG47501A1 (en) 1998-04-17
IL117592A (en) 1999-04-11
SK42693A3 (en) 1993-10-06
BR9205336A (en) 1993-11-16
CA2093221C (en) 1998-09-22
FI980175L (en) 1998-01-27
IL102703A0 (en) 1993-01-14
DE69224450T2 (en) 1998-07-30
JP2633085B2 (en) 1997-07-23
RU2104268C1 (en) 1998-02-10
LT3064B (en) 1994-10-25
HU9300951D0 (en) 1993-06-28
MX9204487A (en) 1993-02-01
CZ288173B6 (en) 2001-05-16
EP0526348A1 (en) 1993-02-03
HK1008741A1 (en) 1999-05-14
IL117592A0 (en) 1996-07-23
JPH06501960A (en) 1994-03-03
FI931476A7 (en) 1993-04-01
HUT68927A (en) 1995-08-28
AU1154195A (en) 1995-05-04
CA2093221A1 (en) 1993-02-03
NZ243795A (en) 1995-04-27
HU211884A9 (en) 1995-12-28
AU658664B2 (en) 1995-04-27

Similar Documents

Publication Publication Date Title
FI104069B1 (en) Process for the preparation of therapeutically useful 3- (phenyl- or cycloalkyl) -3-hydroxy-1-phenylsulfonyl-2-indoline carboxamide derivatives
TW370529B (en) Pyrazolopyrimidines
HUT67648A (en) Process for producing novel imidazole and pyrimidine derivatives and pharmaceutical copositions containing them
PT81748A (en) Process for the preparation of novel oxetanones of novel intermediates which are usable in this process and of pharmaceutical compositions based on said oxetanones or based on precursors thereof
CY2278B1 (en) Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selectibe human nk3-receptor antagonists
GB1526978A (en) 3-thiosubstituted cephalosporin antibiotics
HUP9901630A2 (en) Novel indole-2,3-dione-3-oxime derivatives
NZ333926A (en) Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use
ES8604104A1 (en) Tertiary amines.
ES8101045A1 (en) PROCEDURE FOR THE PREPARATION OF SUBSTITUTED PI-RROLIDINILSULFAMOILBENZOIC ACID DERIVATIVES
GB1505848A (en) 3,4-dicarboxycephalosporins and derivatives
DE1906194A1 (en) Antibiotic cephalosporin cpds.
IT1205015B (en) New nootropic N-substd. isoxazole-5-carboxamide(s)
HUP9902606A2 (en) Matrix metalloproteinase inhibitors
GB1360759A (en) 3-oxy-iminomethyl cephalosporin compounds

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: SANOFI

MA Patent expired